Contact: Ralph Barry, Chief Business Officer, Aegis Therapeutics LLC
1-858-618-1400 Ext. 102, Email: rbarry@aegisthera.com

Aegis Awarded Russian Patent for Non-Invasive Delivery of Triptan Anti-Migraine Drugs

SAN DIEGO, CA  Sept. 1, 2015/MarketWire — Aegis Therapeutics LLC announced today that it has been awarded its first Russian patent providing expanded coverage for non-invasive delivery of triptan anti-migraine drugs via a simple metered nasal spray. Newly issued Russian Patent No. 2554814, titled: “Compositions for drug administration”, covers fast acting drug formulations utilizing Aegis’ Intravail® transmucosal absorption enhancer technology. The Aegis Intravail-based formulation achieves clinically effective drug levels in about 2 minutes –  about 20 times faster than the currently available nasal triptan product.

Aegis now has twenty-five issued patents related to non-invasive delivery of peptide, protein, nucleotide, and small molecule drugs, as well as stabilization and immunogenicity reduction for monoclonal antibody and other protein biotherapeutics, with more than 50 additional patent applications currently pending worldwide.

About Aegis Therapeutics

Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented drug delivery and drug formulation technologies through product-specific licenses. Our Intravail® drug delivery technology enables the non-invasive systemic delivery of a broad range of protein, peptide and non-peptide drugs that can currently only be administered by injection, via the oral, buccal, and intranasal administration routes, and with high bioavailability.  Our ProTek® excipients stabilize, prevent aggregation, and reduce unwanted immunogenicity of monoclonal antibodies and other protein and peptide therapeutics while avoiding the oxidative damage and resulting unwanted immunogenicity caused by polysorbate surfactants currently found in most protein injectable drugs.

For more information about Aegis, please visit: http://aegisthera.com/.